STADA and Alvotech launching Hukyndra high-concentration, citrate-free adalimumab

German drugmaker STADA Arzneimittel (SAZ: Xetra) is offering Hukyndra, the high-concentration, citrate-free formulation biosimilar of adalimumab developed by Iceland-based Alvotech Holding, to patients and their caregivers in selected European countries, including France, Germany, Finland, and Sweden. Launches in further European countries are scheduled over the coming months.

The biosimilar to AbbVie’s (NYSE: ABBV) mega-blockbuster Humira, with its 100mg/mL adalimumab in 40mg/0.4 mL custom-designed pre-filled auto-injector pen as well as 40mg/0.4 mL and 80mg/0.8 mL pre-filled syringe presentations, offers a comprehensive range of biosimilar presentations and devices designed with ease of patient use in mind.

Adalimumab marks the first biosimilar to be commercialized by STADA under a development and manufacturing partnership with Alvotech that, in total, spans seven biosimilars and biosimilar candidates across autoimmunity, oncology, and ophthalmology indications. The partners’ goal is to make available these European-made biosimilars to European patients and caregivers over the coming months and years.